We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recommendations for HER2 testing in the UK.
- Authors
Ellis, I O; Dowsett, M; Bartlett, J; Walker, R; Cooke, T; Gullick, W; Gusterson, B; Mallon, E; Lee, P B
- Abstract
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.
- Publication
Journal of clinical pathology, 11, Vol 53, Issue 12, p890
- ISSN
0021-9746
- Publication type
Journal Article
- DOI
10.1136/jcp.53.12.890